The construction of a new oncolytic herpes simplex virus expressing murine interleukin‐15 with gene‐editing technology
Authors:
- 29 January 2020
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (12) , 3617-3627
Abstract
The treatment of tumors with oncolytic viruses is an important cancer immunotherapy strategy. Interleukin‐15 (IL‐15) can enhance the antitumor effect of natural killer cells and T cells. An oncolytic herpes simplex type II virus (oHSV2‐mIL‐15CherryFP) expressing mouse IL‐15 was constructed using the CRISPR/Cas9 system, and its antitumor activity in vitro and in vivo was evaluated. In vitro, the mouse interleukin‐15 (mIL‐15) present in the culture supernatant expressed by oHSV2‐mIL‐15CherryFP was able to enhance the killing of CT26‐GFP tumor cells by T cells. In addition, the intratumoral injection of oHSV2‐mIL‐15CherryFP inhibited tumor growth in the CT26‐iRFP and BGC823‐iRFP model. These results indicate that the use of oncolytic herpes simplex virus expressing IL‐15 may be a potential therapeutic strategy in tumor immunotherapy.Keywords
This publication has 37 references indexed in Scilit:
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Protein Coexpression Using FMDV 2A: Effect of “Linker” ResiduesBioMed Research International, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Ultrastructural Analysis of ICP34.5 − Herpes Simplex Virus 1 Replication in Mouse Brain Cells In VivoJournal of Virology, 2010
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic MelanomaJournal of Clinical Oncology, 2009
- Evolutionary struggles between NK cells and virusesNature Reviews Immunology, 2008
- An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cellsGene Therapy, 2007
- A Mutant Type 2 Herpes Simplex Virus Deleted for the Protein Kinase Domain of the ICP10 Gene Is a Potent Oncolytic VirusMolecular Therapy, 2006
- ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Therapy, 2003
- Infected Cell Protein (ICP)47 Enhances Herpes Simplex Virus Neurovirulence by Blocking the CD8+ T Cell ResponseJournal of Experimental Medicine, 1998